August 29, 2024
Video
Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
August 29, 2024
Video
Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.
August 29, 2024
Video
Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.
August 22, 2024
Video
Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.
August 22, 2024
Video
Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.
August 15, 2024
Video
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
August 15, 2024
Video
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
June 24, 2024
Video
Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.
June 17, 2024
Video
Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.
June 17, 2024
Video
Key opinion leaders revisit the HER2CLIMB trial, providing an in-depth analysis of the latest updates and their implications for the management of HER2-positive metastatic breast cancer.
June 10, 2024
Video
Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.
June 10, 2024
Video
Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
June 03, 2024
Video
Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.
June 03, 2024
Video
Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.
May 28, 2024
Video
Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.
May 28, 2024
Video
Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.
May 20, 2024
Video
Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.
May 20, 2024
Video
Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.
March 25, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
March 25, 2024
Video
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.